Pharmacokinetics of Midazolam in preterm neonates with an insight in brain Tissue: A PBPK approach

Area of Science:

• Pharmacology
• Neonatal Physiology
• Computational Modeling

Background:

• Pediatric dose calculations traditionally rely on anatomical growth, but physiological immaturity in neonates significantly impacts drug efficacy and safety.
• Ethical and logistical challenges limit pharmacokinetic studies in neonates, resulting in insufficient drug disposition data.
• Understanding drug behavior in neonates is crucial to prevent under- or over-dosing.

Purpose of the Study:

• To develop and validate a Physiologically Based Pharmacokinetic (PBPK) model for predicting IV Midazolam disposition in preterm neonates.
• To assess Midazolam concentration in neonatal brain tissue, the primary site of its action.
• To demonstrate the utility of in-silico methods for determining neonatal pharmacokinetic parameters.

Main Methods:

• Physiologically Based Pharmacokinetic (PBPK) modeling was employed to simulate Midazolam disposition.
• The PBPK model was validated against experimental pharmacokinetic data from preterm neonates of varying gestational ages.
• Brain tissue concentrations of Midazolam were predicted by the model.

Main Results:

• The PBPK model demonstrated comparable predictions for plasma pharmacokinetic parameters against observed experimental data.
• The model successfully predicted Midazolam disposition in preterm neonates.
• Neonatal brain tissue concentrations of Midazolam were successfully estimated.

Conclusions:

• Physiologically Based Pharmacokinetic modeling is a valuable tool for predicting drug disposition in preterm neonates.
• In-silico approaches can overcome limitations in conducting traditional pharmacokinetic studies in this population.
• This PBPK modeling approach can inform optimal drug dosing strategies and administration frequencies for neonates.